LM 002 - LaNova Medicines Limited
Alternative Names: LM-002 - LaNova Medicines LimitedLatest Information Update: 12 Apr 2023
At a glance
- Originator LaNova Medicines Limited
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action 4-1BB ligand expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Colorectal cancer; Gastrointestinal cancer; Lung cancer
Most Recent Events
- 12 Apr 2023 Preclinical trials in Gastrointestinal cancer, Lung cancer, and Colorectal cancer in China (Parenteral) (LaNova Medicines pipeline, April 2022)
- 04 Oct 2022 LM 002 - LaNova Medicines Limited is available for licensing as of 04 Oct 2022. https://www.lanovamedicines.com/foreign-cooperation?tp=2